vs
Digimarc CORP（DMRC）与LEXICON PHARMACEUTICALS, INC.（LXRX）财务数据对比。点击上方公司名可切换其他公司
Digimarc CORP的季度营收约是LEXICON PHARMACEUTICALS, INC.的1.6倍（$8.9M vs $5.5M），Digimarc CORP净利率更高（-47.2% vs -282.7%，领先235.5%），LEXICON PHARMACEUTICALS, INC.同比增速更快（254.4% vs 2.9%），过去两年LEXICON PHARMACEUTICALS, INC.的营收复合增速更高（124.2% vs -5.3%）
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
Lexicon制药是一家成立于1995年的生物制药企业，总部位于美国得克萨斯州伍德兰兹，最初名为Lexicon Genetics，专注于开发人类疾病治疗药物。公司凭借专利小鼠基因敲除技术与强大的体内筛选能力，在Genome5000项目中完成了近5000个基因的研究，筛选出大量候选药物靶点。
DMRC vs LXRX — 直观对比
营收规模更大
DMRC
是对方的1.6倍
$5.5M
营收增速更快
LXRX
高出251.5%
2.9%
净利率更高
DMRC
高出235.5%
-282.7%
两年增速更快
LXRX
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.9M | $5.5M |
| 净利润 | $-4.2M | $-15.5M |
| 毛利率 | 63.5% | 96.3% |
| 营业利润率 | -48.2% | -269.1% |
| 净利率 | -47.2% | -282.7% |
| 营收同比 | 2.9% | 254.4% |
| 净利润同比 | 51.4% | 54.0% |
| 每股收益（稀释后） | $-0.18 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DMRCLXRX
| Q4 25 | $8.9M | $5.5M | ||
| Q3 25 | $7.6M | $14.2M | ||
| Q2 25 | $8.0M | $28.9M | ||
| Q1 25 | $9.4M | $1.3M | ||
| Q4 24 | $8.7M | $1.6M | ||
| Q3 24 | $9.4M | $1.7M | ||
| Q2 24 | $10.4M | $1.6M | ||
| Q1 24 | $9.9M | $1.1M |
净利润DMRCLXRX
| Q4 25 | $-4.2M | $-15.5M | ||
| Q3 25 | $-8.2M | $-12.8M | ||
| Q2 25 | $-8.2M | $3.3M | ||
| Q1 25 | $-11.7M | $-25.3M | ||
| Q4 24 | $-8.6M | — | ||
| Q3 24 | $-10.8M | $-64.8M | ||
| Q2 24 | $-9.3M | $-53.4M | ||
| Q1 24 | $-10.3M | $-48.4M |
毛利率DMRCLXRX
| Q4 25 | 63.5% | 96.3% | ||
| Q3 25 | 58.3% | 99.9% | ||
| Q2 25 | 58.8% | 99.9% | ||
| Q1 25 | 65.0% | 97.6% | ||
| Q4 24 | 60.8% | 77.5% | ||
| Q3 24 | 62.4% | 95.9% | ||
| Q2 24 | 66.1% | 89.7% | ||
| Q1 24 | 62.5% | 97.2% |
营业利润率DMRCLXRX
| Q4 25 | -48.2% | -269.1% | ||
| Q3 25 | -109.7% | -85.9% | ||
| Q2 25 | -105.2% | 12.9% | ||
| Q1 25 | -128.9% | -2034.8% | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -120.4% | -3658.4% | ||
| Q2 24 | -96.2% | -3423.3% | ||
| Q1 24 | -109.2% | -4147.6% |
净利率DMRCLXRX
| Q4 25 | -47.2% | -282.7% | ||
| Q3 25 | -106.9% | -90.0% | ||
| Q2 25 | -102.6% | 11.3% | ||
| Q1 25 | -125.2% | -2004.4% | ||
| Q4 24 | -99.9% | — | ||
| Q3 24 | -113.9% | -3722.6% | ||
| Q2 24 | -89.3% | -3304.2% | ||
| Q1 24 | -104.0% | -4427.9% |
每股收益（稀释后）DMRCLXRX
| Q4 25 | $-0.18 | $-0.04 | ||
| Q3 25 | $-0.38 | $-0.04 | ||
| Q2 25 | $-0.38 | $0.01 | ||
| Q1 25 | $-0.55 | $-0.07 | ||
| Q4 24 | $-0.40 | — | ||
| Q3 24 | $-0.50 | $-0.18 | ||
| Q2 24 | $-0.43 | $-0.17 | ||
| Q1 24 | $-0.50 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.9M | $96.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $40.2M | $107.5M |
| 总资产 | $53.0M | $185.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DMRCLXRX
| Q4 25 | $12.9M | $96.2M | ||
| Q3 25 | $12.6M | $116.0M | ||
| Q2 25 | $16.1M | $139.0M | ||
| Q1 25 | $21.6M | $194.8M | ||
| Q4 24 | $28.7M | $238.0M | ||
| Q3 24 | $33.7M | $258.4M | ||
| Q2 24 | $41.5M | $310.0M | ||
| Q1 24 | $48.9M | $355.6M |
股东权益DMRCLXRX
| Q4 25 | $40.2M | $107.5M | ||
| Q3 25 | $41.4M | $120.2M | ||
| Q2 25 | $46.5M | $129.4M | ||
| Q1 25 | $50.0M | $123.0M | ||
| Q4 24 | $61.4M | $145.9M | ||
| Q3 24 | $70.2M | $178.5M | ||
| Q2 24 | $77.2M | $240.0M | ||
| Q1 24 | $84.5M | $288.9M |
总资产DMRCLXRX
| Q4 25 | $53.0M | $185.0M | ||
| Q3 25 | $55.4M | $205.9M | ||
| Q2 25 | $60.7M | $225.6M | ||
| Q1 25 | $66.5M | $297.7M | ||
| Q4 24 | $75.8M | $298.4M | ||
| Q3 24 | $85.0M | $321.1M | ||
| Q2 24 | $93.4M | $373.4M | ||
| Q1 24 | $99.7M | $417.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $991.0K | $-17.2M |
| 自由现金流经营现金流 - 资本支出 | $895.0K | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-12.3M | — |
8季度趋势，按日历期对齐
经营现金流DMRCLXRX
| Q4 25 | $991.0K | $-17.2M | ||
| Q3 25 | $-2.6M | $-23.8M | ||
| Q2 25 | $-4.7M | $17.0M | ||
| Q1 25 | $-5.5M | $-43.8M | ||
| Q4 24 | $-4.2M | $-178.8M | ||
| Q3 24 | $-7.1M | $-53.6M | ||
| Q2 24 | $-6.8M | $-48.5M | ||
| Q1 24 | $-8.4M | $-55.1M |
自由现金流DMRCLXRX
| Q4 25 | $895.0K | — | ||
| Q3 25 | $-2.8M | — | ||
| Q2 25 | $-4.9M | — | ||
| Q1 25 | $-5.5M | — | ||
| Q4 24 | $-4.2M | $-179.8M | ||
| Q3 24 | $-7.2M | $-53.9M | ||
| Q2 24 | $-6.9M | $-48.8M | ||
| Q1 24 | $-8.5M | — |
自由现金流率DMRCLXRX
| Q4 25 | 10.0% | — | ||
| Q3 25 | -36.9% | — | ||
| Q2 25 | -61.0% | — | ||
| Q1 25 | -59.1% | — | ||
| Q4 24 | -49.1% | -11600.7% | ||
| Q3 24 | -75.7% | -3097.4% | ||
| Q2 24 | -66.1% | -3017.3% | ||
| Q1 24 | -85.8% | — |
资本支出强度DMRCLXRX
| Q4 25 | 1.1% | — | ||
| Q3 25 | 2.9% | 0.0% | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.2% | 66.5% | ||
| Q3 24 | 0.7% | 17.6% | ||
| Q2 24 | 0.3% | 15.5% | ||
| Q1 24 | 1.1% | 0.0% |
现金转化率DMRCLXRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.23× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
LXRX
暂无分部数据
